



**I had this little-known biotech as a STRONG BUY at \$3.80
—now as the market adjusts this stock's
temporary dip to \$2.60 makes it a MUST BUY!**

And now this biotech opens for business this fall!

**For the last 52 weeks this stock has steadily surged from
6 cents to \$3.80 when I first recommended it.**

**Now with a temporary dip to \$2.60 this stock could see an 1,176.92% GAIN in
the next 12 to 18 months—based on my EXTREMELY CONSERVATIVE
projection that just can't be ignored!**

Dear Fellow Profit Seeker,

For the last 3 months I've kept up with the progress of a remarkable biotech stock with a breakthrough medical cure for hair loss.

I have seen it slowly grow from a penny stock to a \$1 a share...to \$2 a share...to \$3 a share and beyond—the early birth pangs of what I believe could be explosive growth in the next 12 to 18 months.

And that's based on my EXTREMELY CONSERVATIVE projection estimates (check my math below!).

Now this stock has taken a momentary dip making it a MUST BUY at just \$2.60!

Even better, this biotech just announced on July 1st that they are setting up shop in the fall and OPENING for BUSINESS!

Commercial operations launch in October making available to the public—for the very first time—the world's first REAL CURE for baldness!

Buy now and you could turn \$10,000 into \$127,692 in the next 12 to 18 months.

Forget the naysayers and the doubters. They don't know this company and this stock like I do. I'm all in with my money—and so are many of the members of my **Speed Retirement System**.

And because of the breakthrough science this biotech is working to bring to market, I've called this little-known biotech...

My Stock Recommendation of the Decade!

My name is Ian Cooper. My job is helping investors like you create a comfortable retirement nest egg following the strategies of my **Speed Retirement System**.

[Learn more about Ian Cooper. CLICK HERE](#)

In fact, with over 577 documented trades, I've picked winners 76.2% of the time. And my average net gain is 32%...and that includes all the losers.

Yes, if you simply followed along with my recommendations over the last 5 years...

You could've turned \$10,000 into \$2.2 MILLION!

You see, others might settle for just breaking even this year, or pulling in the paltry 7.3% that the Dow Jones averaged last year.

Call your broker or go online and ask for...

BIOLOGIX HAIR INC.

Stock Symbol:	OTCBB: BLGX
Current Price:	\$2.60 (as of 7/5/2013)
Conservative 18-Month Projection:	\$33.20
Very Conservative 12-Month Projection:	\$16.60
Immediate STRONG BUY Target Price:	\$8.30

Note: As with any investment there is always a particle of risk, but also a potential to reap rich returns. To minimize risk, I recommend limiting your investment to 10% of your portfolio.



[Learn more about Ian Cooper. CLICK HERE](#)

But frankly, that's not me. Who can possibly retire on that?!!!

That's why I've dedicated myself to helping investors turbo-charge their investing... accelerate their way to retirement... and reach their retirement dreams sooner!

I'll show you how using a highly sophisticated **"hyper-compounding"** strategy—coupled with **money management techniques** used by some of the world's most successful hedge fund traders—can give you a decisive edge over virtually every other investor in the market today.

So if you missed out on that \$2.2 million I was telling you about... don't worry. You can still get in on it!

Starting with my small cap biotech recommendation of the DECADE!

Biologix Hair Inc. (BLGX) **"My Global Biotech Bonanza Stock for 2013-14"**

When I first got word of Biologix Hair Inc. (BLGX), it was dead on arrival. No way, José. Mankind has been looking for a cure for baldness since ancient times without success. And modern man hasn't fared much better...

- ◆ Propecia has a drug in it called *finasteride* that causes permanent sexual dysfunction...and the hair growth is like peach fuzz.
- ◆ Rogaine (Minoxidil) can cause chest pains and increased heart rate. And once you stop using it, the peach fuzz you grew falls out.
- ◆ And hair transplant surgery? It's risky as any surgery is. The results look ridiculous. And you still have to take finasteride for the rest of your life to maintain your hair. And again, that could mean a sad sex life.

Still, hair restoration is an annual \$3.5 BILLION industry in the United States ALONE. And the total global market numbers are astronomical!

So, I wasn't expecting too much when I ran across Biologix and their patent-pending hair loss prevention and regeneration treatment called the Biologix Hair Therapy System™.

But I was dead wrong.

After a little digging I discovered Biologix is the real deal—**perhaps the first ever legitimate "cure" for hair loss. I'm still in shock...I just can't believe it!**

[Read a special letter from the Creator of this miracle cure! CLICK HERE](#)

This emerging biotech small-cap company has already tested on over **5,000 people** during pre-clinical trials over an **8-year period** ...with a **90% success rate** of growing natural, full, real hair... **proven safe**...and

NEWSFLASH – UPDATED July 1, 2013

!!!OPEN FOR BUSINESS!!!

Biologix announced today that they are making their groundbreaking hair restoration therapy available to the public for the very first time starting October 2013.

The first Biologix clinic opening in Colombia (where the treatment was first discovered) will also serve as a training center for licensed clinicians who've contracted with Biologix to operate certified Biologix Hair Therapy Centers™.

Biologix still has their eyes fixed on securing regulatory approvals in major Western markets. But with doors opening in locations throughout the world they aren't missing the opportunity to capitalize on major revenue potential. For more details [CLICK HERE](#)

no negative side effects!

It's not a shampoo, scalp massager or spray-on hair. It's a simple out-patient medical procedure based on 20+ years of research into hair loss.

And it's not dangerous surgery.

It uses an injectable drug formulation known as Biologix Revive™ which includes a nutritional package of essential vitamins and minerals as well as two highly researched pharmacological agents that work to reverse hair loss.

All it takes is 50 shallow scalp injections—like acupuncture—to jumpstart “dead” hair follicles into growing hair again. *More on this in a moment.*

Best of all, it works.

In over 5,000 pre-clinical trial patients who were given more than 30,000 treatments over an eight-year period, Biologix saw 80-85% success in men and 90-plus% success in women.

The therapy—up for possible FDA approval over the next 3 or more years—should have no problem tapping into the massive **\$3.5 billion U.S. hair loss market**—not to mention the rest of the world. And as you'll soon see, this is a **globally focused** biotech company.

And while they work towards obtaining regulatory approvals, Biologix is launching a four-pronged campaign to ensure ongoing market success.

- 1 Biologix is working with top research universities, legal advisors and leading scientists to advance its patent-pending formula to seek not only FDA approval, but global approvals from various regional regulatory agencies worldwide. But the Biologix team is focused on getting FDA approval first and the rest fall into line.
- 2 Biologix is funding the development of a worldwide product distribution network by contracting with licensed medical practitioners and building a massive universe of ready-made end-users right now!
- 3 Biologix is creating subsidiary companies in tax efficient locations to manage inventory control systems and to oversee the quality control requirements expected of its certified Biologix Hair Therapy Centers.

 **Biologix is OPENING for BUSINESS starting October 2013. Commercial operations will launch this fall making available for the very first time to the public the world's first REAL CURE for baldness!**

Biologix's global market potential includes hundreds of millions of men and women suffering the effects of unwanted hair loss **and perhaps an even bigger number who have hair and don't want to lose it!**

Just in the United States alone there are 35 million men and 25 million women who today are suffering from hair loss. I'm one of them...maybe you are, too!

And as you'll soon see, Biologix has been contracting with leading medical doctors all over the world seeking to be first in line to obtain exclusive purchasing and treatment rights to the Biologix Hair Therapy



How does Biologix Revive™ work? Watch this short video to see the science behind this miracle cure for baldness.

System™.

And that international network is lining up human patients waiting to try the procedure—total a universe of more than 3.28 million people to-date—and that future revenue base is expanding at a wildfire pace!

So, read on and discover why this is NOT just another hair growth scam and why the Biologix Hair Therapy System™ is my top pick for members of my **Speed Retirement System** and...

The first medical cure for baldness that REALLY works.

If you're losing your hair, most doctors will simply tell you that your hair follicles are dead. Dead follicles can't produce hair. That has always been the assumption.

But the team of medical researchers at Biologix decided to challenge the status quo.

It all began back in 1992 in Barranquilla, Colombia when a small team led by Dr. Guillermo Duran began investigating the causal-effect of alopecia—commonly known as baldness or hair loss.

What ensued over the next six years was extensive research and analysis that led to a breakthrough discovery. **Here's what they found.**

Hair follicles are tiny organs (like your lungs, kidneys and liver) that are embedded in your skin. And their only job is to produce hair.

But when inflammation occurs in the tissue around the hair follicle, the vital blood supply that nourishes the organ is blocked.

The follicle doesn't die...but becomes **dormant**.

In other words, the hair follicles are being choked off in a "sleeper hold" that ultimately stops hair growth.

What causes this inflammation? A number of things...emotional stress, environmental conditions, genetic predisposition to stress, even an injury can create the right conditions that trigger inflammation.

Naturally, the body tries to fight off this inflammation by producing inflammation-fighting proteins. But they end up blocking the follicle opening and creating a log jam in the follicle shaft that prevents hair from growing.

The result is hair loss.

It took Dr. Duran and his research team at Biologix over 6-year period from 1992 to 1998 to discover this one simple fact—the first to do so. And they gave it a name...

Follicle Nutrient Deficiency Syndrome—the *real* cause of baldness!

It wasn't until 2011 that an independent team from the University of Pennsylvania came to the same headline making discovery.

But what's really earth-shattering is that once this problem is solved...once the inflammation is relieved...and once the hair follicles get the nourishment they need...

...most, if not all, of the hair will grow back naturally, thick and full, in the same color it always was.

After 30,000+ applied treatments and over 5,000 test patients, the company found that between 80% and 85% of male patients, and 90% of female patients treated for Follicle Nutrient Deficiency Syndrome regrew their lost hair.

And the rate of success with patients suffering from *alopecia* (male pattern baldness) was nearly 100%. Keep in mind that according to the National Alopecia Areata Foundation, this autoimmune disorder **affects approximately 2% of the population here in the United States**. That's **5 million Americans** alone (to say nothing about the rest of the world).

PLUS...there's the Preventive Care Market. Imagine hundreds of millions of people around the world who use this treatment to keep the hair they have. A simple biannual trip to a Biologix Hair Therapy Center (like a regular dentist checkup) is all that's needed to keep your locks for life!

And commercially available treatments will be available to the public starting October 2013.

It seems fitting that the place where this discovery was made is also the location of the very first Biologix Clinic—Colombia! This clinic will also serve as a training center for licensed clinicians who've contracted with Biologix to operate certified Biologix Hair Therapy Centers™ (more on this in a moment).

Of course, Biologix is still focused on securing FDA and other regulatory approvals in major Western markets. But with doors opening in locations throughout the world they aren't missing the opportunity to **generate revenue**.

[And here's a TREND no one is talking about – CLICK HERE](#)

And if you act before FDA approval I believe you could see yourself with a windfall of...

1,176.92% or more Turning \$10,000 into \$127,692

But that's not the whole story. Not by a longshot. My specialty is getting members of my **Speed Retirement System** closer to their retirement dreams through smart money management and my exclusive **Hyper-Compounding** strategy.

I believe in reducing risk and maximizing opportunity with every stock pick and every trade—**and that mean getting the facts and running the numbers**.

I always investigate why **NOT** do something and try to find the reasons **NOT** to proceed. In this case, I didn't even find any amber lights—let alone red warning signs!

Biologix (BLGX) is an outright GREEN to GO!

Here are **5 my compelling ultra-conservative analytical reasons** why you should consider adding **Biologix Hair Inc. (OTCBB: BLGX)** to your portfolio now:

Reason #1:

Anticipatory Momentum

Make money with Biologix—with or without FDA approval!

Remember the Facebook IPO flop? There was a lot of excitement building up to its initial public offering.

But I wasn't buying the hype. Still, I knew how I could leverage the major buzz for me and my **Speed Retirement System** members.

In the end, we made \$4.60 for every \$10 we invested...and Mark Zuckerberg lost \$5.6 billion on the same deal!

In a way, Biologix is in a similar position.

NOT because I think Biologix is going to flop...but because of something that happened with Facebook called *Anticipatory Momentum*.

Anticipatory Momentum is the wave of excitement and interest in a stock during a specific time. For Biologix it's the anticipation of FDA approval for *the world's first legitimate medical cure for baldness*. **Here's how it's happening now...**

Currently, Biologix is working with the Beijing Institute of Technology (BIT) to complete a series of examinations and tests prior to commencing formal FDA clinical trials.

See, on May 11, 2012, Venable LLP, the Washington-based law firm overseeing the worldwide IP and regulatory approval processes on behalf of Biologix, filed a Patent Cooperation Treaty (PCT) application on behalf of the Biologix Revive™ formula in Geneva, Switzerland. The PCT is an international treaty, administered by the World Intellectual Property Organization (WIPO) comprised of 147 countries including Canada and the United States.

Biologix now has 18 months to submit its final formula for worldwide patent protection...**the anticipation grows**. And that final formula cannot be filed until BIT completes their laboratory work.

Part of what the BIT work consists of is bringing together all of the ingredients in the formula into a single formulation that has been tested at various levels of temperature and in varying light conditions for stability and shelf life, amongst other things.

Now, because there's no reason to expect any significant delays in the BIT process...**anticipation's growing...** and the process is expected to be primarily completed within the next 9 to 12 months, it's reasonable to assume the final formulation to be filed in Geneva in about 12 to 14 months from now.

Now this all plays a BIG part of my value matrix calculations as you'll see shortly. Each step in the process reduces risk assessment and drive the stock price up. And my simple math shows you why. (More in a moment)

As the FDA decision date draws near (or a Phase III result date or Prescription Drug User Fee Act or peer

Call your broker or go online and ask for...

BIOLOGIX HAIR INC.

Stock Symbol:	OTCBB: BLGX
Current Price:	\$2.60 (as of 7/5/2013)
Conservative 18-Month Projection:	\$33.20
Very Conservative 12-Month Projection:	\$16.60
Immediate STRONG BUY Target Price:	\$8.30

Note: As with any investment there is always a particle of risk, but also a potential to reap rich returns. To minimize risk, I recommend limiting your investment to 10% of your portfolio.

NEWSFLASH

BIT Completes First Four Waves of Critical Testing

This just in...

On June 7, 2013 Biologix released the latest R&D update on BIT's progress with their tests of Biologix Revive™.

These are vital tests leading into formal FDA clinical trials.

And it was just revealed BIT has completed the first four waves of critical testing.

This is a key component in my valuation of Biologix as the company moves closer to submitting worldwide patent protection. And it's why I'm issuing a STRONG BUY alert now.

Read below and learn how I factor this important step in my valuation of Biologix.

review conference) savvy investors will bid up the price in spectacular fashion.

Here's how a recent example of anticipatory momentum played out very recently with biotech Vertex Pharmaceuticals ...

On April 19, 2013 Vertex's share price shot up a staggering 55% from \$52.87 to \$85.60 in one day on more than 24.8 million shares of trading volume!

What happened? The news was out that Vertex was moving on to Phase III clinical trials after positive clinical results from its Phase II FDA study.

The drug Vertex is developing is an experimental treatment for cystic fibrosis patients—an estimated 70,000 potential customers—if the drug is successful and reaches full market penetration.

And as you'll read here...

Biologix Hair (BLGX) is preparing to enter FDA trials, anticipating starting at Phase III based on all their previously conducted research and pre-clinical trial studies.

And the Biologix universe of potential end-user customers is in the hundreds of millions of people GLOBALLY!

Are you starting to see why I am so unbelievably excited about this winning discovery I've made? Read on...

Of course, like Vertex, if you come in **after** the approval process winds along, then you'll miss a big part of this company's wave. So, like any other timely opportunity in life, getting in early is important.

While there's no such thing as 100% FDA trading success, I can tell you—without a doubt—that this \$2.60 stock could see \$16.60...even \$33.20...over the next 12 to 18 months.

So here's the beauty of an FDA trade...

It doesn't matter what the FDA says or does.

What matters is being in the know and being in the right place at the right time.

And here's a little-known secret of the world's top hedge fund traders who make their fortunes using the FDA calendar and Phase III trial...

The price of a biotech and pharmaceutical company will almost always go up as the date of approval draws closer—as witnessed by the Vertex announcement just recently.



GINA'S STORY: Take a very personal look into how Biologix is dramatically changing lives for the better.

This happens over and over again with many biotechs and pharmaceuticals. The only key is having the information in as far in advance as you can. **And Biologix is poised to begin Phase III trials within 18 months – possibly sooner!**

Here's more proof. Take a look at the iShares NASDAQ Biotech Index below. As you can see it has outperformed the S&P 500 for quite some time. And things are only looking up.



And with millions around the world looking for the answer to baldness, Biologix has prepared a smart global "franchise-style" model to ensure this product gets to market, which leads us to...

Reason #2: Franchising the Biologix Hair Therapy System™

Biologix is creating its own global distribution channel ahead of FDA approval using a tried-and-true franchise-style approach.

They're reaching out to licensed medical clinics all around the world and getting them on board with this revolutionary NEW hair restoration procedure.

To make this happen, Biologix has created a Clinician Licensing Department headquartered in Toronto, Canada for the sole purpose of contracting with clinics that want to become future exclusive locations where the *Biologix Hair Therapy System*™ can be offered to literally millions of people who are suffering from hair loss.

And licensed clinicians and medical practitioners are virtually lining up all over the world to become *Certified Biologix Hair Therapists*™. They want to secure their exclusive territorial purchasing and treatment rights for the *Biologix Hair Therapy System*™. That means a promising revenue stream for them and Biologix!

As of May Biologix has contracted with 276 medical clinics, located in 37 countries, which amounts to 3,284,065 clients!

Even better, when asked on a clinic-by-clinic basis how many existing patients would be

Call your broker or go online and ask for...

BIOLOGIX HAIR INC.

Stock Symbol:	OTCBB: BLGX
Current Price:	\$2.60 (as of 7/5/2013)
Conservative 18-Month Projection:	\$33.20
Very Conservative 12-Month Projection:	\$16.60
Immediate STRONG BUY Target Price:	\$8.30

Note: As with any investment there is always a particle of risk, but also a potential to reap rich returns. To minimize risk, I recommend limiting your investment to 10% of your portfolio.

interested in the obtaining the Biologix Hair Therapy the clinics reported a staggering 1,315,926 people!

Keep in mind that Biologix will be OPEN for BUSINESS starting October 2013.

And their first clinic—opening in Cartagena, Colombia—will not only make this groundbreaking hair restoration therapy available to the public for the very first time, but also serve as a **training center** for licensed clinicians who've contracted with Biologix to operate certified Biologix Hair Therapy Centers™.

Remember the Vertex story? Their patient universe was estimated to be roughly 70,000. That, along with clinical trials progressing to Phase III, rocketed the stock 55% on more than 24.8 million shares of trading volume!

So how do they reach these clinicians...and why are they so excited to sign up?

Biologix was created and run by medical doctors. So they reached out to their fellow clinicians and medical practitioners by presenting their scientific findings at many of the leading hair loss and cosmetic medicine conferences around the world—in cities such as: Edinburgh, Las Vegas, Monte Carlo, Orlando, Toronto and Vancouver.

And the Biologix presentation has been a show-stopper at every medical conference where it's been featured.

The contracting clinicians see Biologix as offering a high margin product that solves one of the greatest, and most unpleasant, medical mysteries of the human condition—unwanted hair loss. Read what they have to say...

"I first met the company in Monte Carlo and was amazed and impressed at the amount of care and research that had been done to get the Biologix Hair product to the marketplace ... I am very excited at the prospect of being able to offer my patients a predictable, reliable and safe product for their hair loss problems. I am equally excited at the enhanced revenues and reputation this will bring to my medical clinic."

**--Dr. Joshua Berkowitz, Founder and Clinical Director,
Wimpole Aesthetics, London UK**

"I have been waiting for an effective minimally invasive therapy for mild-moderate hair loss. At the ISHRS annual meeting in Nassau, I was excited to learn of the potential to treat this segment of my patient population with the new product coming from Biologix. I am anxious to be one of the first to use this exciting new product, and to be a regional distributor."



JESÚS' STORY: Take a very personal look into how Biologix is dramatically changing lives for the better.

--Dr. Allan Patrick, Director
Atlantic Hair Restoration, Fredericton, NB

"Biologix Hair offers an opportunity to help our aging population, whether 25 years old or 75 years, experience a higher level of overall wellness both inside and outside. I believe our patients will appreciate the opportunity to complement their internal improvements with external, visual improvements."

--Dr. Richard S. Wilkinson
Wilkinson Wellness Clinic, Yakima, WA

"I believe this innovative technology will be ground-breaking for patients suffering with hair loss."

--Danielle Brenza, Director of Operations
Ageless Skin and Laser Center, Sewell, NJ

"Wanting to be the first with a Biologix territory was a no-brainer. We take our business and its results seriously and only want the best for our clients. After speaking with Donna Lieder and better understanding what Biologix was doing, I signed up immediately, and am excited every time I receive new mail about Biologix."

--Grant M. Gunderson, Director of Medical Services,
Hair Restoration Institute of Pennsylvania, Pittsburgh, PA

This distribution strategy has been a howling success for Biologix as they "get out the word" and build a global network of "customers in waiting."

On top of that, as you will read below in **Reason #5**, by establishing its own distribution channel, Biologix is forcing the hand of potential suitors interested in taking over this rising star.

Most biotech companies have no ability to get their drug or treatment process to market. They NEED a major pharma partner to get them there. But not in Biologix's case, which gives them strength at the "takeover table talks."

It's another big momentum driving reason I believe Biologix Hair (BLGX) is well-positioned to deliver **1,176.92% profit in the next 12 to 18 months**. Of course, my forecasted numbers here reflect ONLY the clinician data reported up to now. Any new data issued by Biologix will certainly drive those forecasts north for good reason—and fast!

Watch for clinician licensing announcements in the near future. They are the heartbeat of patient development news as this company advances its FDA approval process.

I'll certainly be updating members of my **Speed Retirement System** as new results are issued on either the Clinician Licensing front or the regulatory approval front. Yet another reason to subscribe to my **Speed Retirement System now**.

Reversing
the CURSE of
Alopecia Areata

Before After
Carlos Quiceno

MY STORY: CARLOS QUICENO

BiologixHair
The hair of tomorrow is here

Reason #3: A Strong and Smart Management Team

One of the most critical—and often overlooked—factors to consider before you invest in a company is the quality of the leadership. I've spoken to some of these people and got first hand answers to the questions the members of my **Speed Retirement System** want to know.

Here's just a brief overview of their backgrounds and why they gave me the confidence to put their stock on my **URGENT BUY** list.

The Biologix Management Team



Ron Holland – Chairman of the Board

Mr. Holland is an author, financial expert, entrepreneur and international business strategist. He has provided strategic business consulting and advisory services to numerous private and publicly traded companies over the past 42 years in diverse areas of finance and marketing including banking, trust department leadership and real estate, as well as in the investment industry, from broker and retirement consultant to president of a national investment firm. Best known as a leader and originator of unique new financial products and concepts, Holland acted as President of JML Swiss Investment Counselors USA after creating the first independent (non-bank) Swiss owned broker-dealer in the US, licensed for both insurance and limited broker-dealer securities in 47 states. Holland is also the author of several books and hundreds of articles focusing on politics, foreign affairs, gold and the investment markets.

Michael Stocker, PhD – Director & Chief Executive Officer

Dr. Stocker has held executive positions in a variety of companies internationally. He has served in top management for organizations including FUNDES International, PROPEL Colombia, and Boston Consulting Group in its offices in Mexico, Spain and Switzerland. Dr. Stocker has served as an adviser and consultant to the Inter-American Development Bank, the United Nations Industrial Development Organization, the Swiss State Secretariat for Economic Affairs, the World Bank's International Finance Corporation and the Organization of American States.



J. Gregory Wilson – Chief Financial Officer

Mr. Wilson is an entrepreneur and corporate finance strategist with more than 20 years experience advising and structuring capital market financings for start-up enterprises and assisting in developing and implementing successful business plans. Wilson began a career in finance working with top Canadian investment firm Scotia McLeod. He went on to work with the Bank of Montreal's investment arm, Nesbitt Burns, before finishing his mainstream financial career with Merrill Lynch. In 2005, Wilson helped found Paramount Gold & Silver Corp., a precious metals exploration company that currently trades on the NYSE and TSX. He also co-founded and led the financing of a renewable energy company with a portfolio of over 600 megawatts of wind projects in Canada, the United States and Germany. Wilson also has experience

Baldness isn't always just about men...or getting older. The hair loss condition known as **Alopecia Areata** is an autoimmune disease that can affect 4.3 million Americans—both men and women of any age, and often children.

It starts with a normal full head of hair that in a short time drops out in clumps—eventually resulting in complete hair loss. The condition is emotionally devastating particularly for women and children who suffer from the disease.

Infections, allergic reactions, stress, physical trauma and long-term chemical exposure are known to sometimes trigger the condition. And when the body's immune system attacks the hair follicles with inflammatory cells, **Follicle Nutrient Deficiency Syndrome (FNDS)** occurs—the very condition identified by Dr. Duran and his research team.

Fortunately, the Biologix Hair Therapy System™ has proven effective in jumpstarting the stalled hair growth cycle in alopecia so that healthy, natural hair is regrown by **nearly 100% of alopecia areata patients in preclinical trials**. These exciting results offer great hope for patients who previously had very treatment options.

negotiating and structuring acquisition and raising the equity component of the purchase price.

Wilhelm A. Keller – Director

Mr. Keller is the founder and majority shareholder of Medmix Systems AG, a globally recognized pioneer in two-component mixing and delivery systems for medical applications. Previously, he founded Mixpac Systems, a Swiss company providing two-component mixing and delivery devices, holding over 50 patents in this field. After 35 years of successful operation, Mixpac Systems was sold to Sulzer AG - a large Swiss publicly traded company with more than 17,000 employees and annual revenues in excess of \$3.5 billion.



Ken Zadoorian – Director

Mr. Zadoorian has built a long track record as a successful executive with an extensive background in large organizations and smaller start-ups. He has proven success in developing mergers and acquisitions and has offered business consulting through Axeo Consulting and Scottsdale Consulting. And during his 25-plus years at Eli Lilly & Company, Mr. Zadoorian held several top-level management positions including director of Human Resources and director of Worldwide Manufacturing and Engineering.

Dr. Guillermo Duran – Inventor & Chief Medical Officer

Dr. Duran is a medical doctor specializing in mesotherapy and esthetic medicine. He served as Executive Director of San Roque Hospital, as an Intensive Care Unit physician at the Ramon Gonzalez Valencia Hospital. Dr. Duran has been a guest speaker on the topic of trichology at several conferences, including in Brazil in 2008, Spain in 2011, and three times in Colombia from 2008-10.



Dr. Pankaj Modi – VP, Treatment Delivery Innovation

Dr. Modi is an experienced clinician and research scientist as well as the founder and president of several medial corporations. Dr. Modi brings 11 years of clinical experience conducting numerous large-scale clinical studies for FDA approvals. He holds more than 25 US and Canadian patents and 280-plus world patents. Dr. Modi has obtained FDA approval for 13 drugs successfully over the past five years and currently has seven applications in process.

Todd A. Harrison – Chief Legal Counsel

Harrison focuses his practice on issues related to the FDA, USDA's Food Safety and Inspection Service, Animal and Plant Health Inspection Service, Agricultural Marketing Service, FTC and the DEA as well as other federal, state, and international consumer protection agencies. His experienced includes drafting opinion letters regarding the status of food ingredients in the United States and the preparation of food additive petitions, GRAS notifications, and new dietary ingredient notifications. He also assists companies in developing self-determined GRAS position for food ingredients. Harrison also has a successful track record of defending against U.S. FTC advertising complaints, enforcement actions and prosecutions, and defending against competitor challenges in court and other forums.





Donna Lieder – Vice President, Clinician Licensing

Donna has over 20 years of international experience working in the financial services industry, beginning in retail banking in British Columbia and followed by bilingual banking in Paris. Her experience also includes working as a Financial Advisor. But her primary expertise is in working with ultra-high net worth clients, including physicians, to provide concise, easily understood overviews that make complicated issues a simple process—ideal for her work at Biologix.

This management team is one of the best and most experienced I've ever evaluated. But, the medical advisory team is a virtual all-star line-up of world-class hair loss specialists.



Dr. Craig Ziering – Chairman

This team has a lot of shining all-stars, but Dr. Zierling may be the brightest. He's a board certified dermatologist, a 20-year professional as a hair transplant surgeon performing over 18,000 procedures and medical director, founder and CEO of Ziering Medical Worldwide headquartered in Beverly Hills. Dr. Ziering is also certified by the American Osteopathic Board of Dermatology and well-known in Hollywood as *The Hair Restoration Surgeon to the Stars*.

Dr. Edward Ball – Medical Advisory Board

Dr. Ball is a hair transplant surgeon and Clinical Director of Ziering UK. He is a member of the Royal College of Surgeons of England. Trained in microsurgery, he is also a member of the skin cancer surgery team at University Hospital Southampton. He has also been published in the medical journals including *The British Journal of Plastic Surgery*, *The British Journal of Dermatology*, and *The Journal of Plastic and Reconstructive Surgery*.



Dr. Alan J. Bauman – Medical Advisory Board

Dr. Bauman is one of only one hundred hair restoration physicians to receive certification by the American and International Board of Hair Restoration Surgery and one of only fifty physicians recommended by the American Hair Loss Association worldwide. Dr. Bauman has authored several textbook chapters on Eyelash Transplant surgery. And he's the founder of the Bauman Medical Group. Dr. Bauman also serves on medical advisory boards for several Fortune 500 companies, such as Merck, Procter & Gamble and others.

Dr. Leila Bloch – Medical Advisory Board

Dr. Bloch is a well-known dermatologist and hair restoration surgeon and founder of Clinica Bloch in Sao Paulo, Brazil. In addition to providing direct patient care in her private clinic, Dr. Bloch is part of the Team Onco-Hematology of the Clinical Hospital Israelita Albert Einstein, where she specializes in chemotherapy-induced alopecia. The team is also involved with clinical research in dermo-cosmetics. Dr. Bloch has also had her work published in national and international journals and participates in conferences and courses worldwide. And in 2004, she was the only Brazilian to join the European Hair Research Congress



in Zurich.



Dr. Arthur G. Handal – Medical Advisory Board

Dr. Handal is a member of the American Society of Plastic Surgeons, American Society for Aesthetic Plastic Surgery, American College of Surgeons, Southeastern Society of Plastic and Reconstructive Surgeons, Palm Beach County Society of Plastic and Reconstructive Surgery, Florida Medical Association, Palm Beach County Medical Society and the American Society of Laser Medicine and Surgery. He is also certified by the American Board of Plastic Surgery.

Dr. David Perez-Meza – Medical Advisory Board

Dr. Perez-Meza is an award-winning hair restoration specialist. He is the Clinical Director of Ziering Medical Spain and associate director of clinical research for Ziering Worldwide. He has served as president of Permanent Hair Solutions in Mexico City, as clinical consultant to Ameriderm Research, and on the Board of Governors of the International Society of Hair Restoration Surgery. He was an active member of the Presidential Medical Corps, serving as the personal physician to former Mexican presidents. Dr. Perez-Meza has authored numerous publications and research studies. And he has served as a consultant for many companies.



Together, this team has a solid record of professional successes from business to medical to finance to marketing. It's just another reason I feel very confident recommending this stock to you and members of my Speed Retirement System.

It's why you could see \$10,000 turn into \$127,692 in the next 12 to 18 months—a 1,176.92% profit

And it's also because of this team that I am excited about this next critical factor that I believe will contribute to Biologix Hair's success...

**Reason #4:
NYSE Listing is around the corner**

Let me make this clear. **Biologix Hair (BLGX) is a fully reporting issuer currently trading on the OTC at \$2.60.** You can pick up the phone and have your broker buy it right now.

However, it's not on Wall Street's radar...yet. And that's great news for you and me... for now.

But it won't stay hidden for long once my report goes mainstream. And it will. There are bound to be others who claim they discovered Biologix first. But they didn't. We did... you and I.

You see, Biologix Hair is actively seeking

Call your broker or go online and ask for...

BIOLOGIX HAIR INC.

Stock Symbol:	OTCBB: BLGX
Current Price:	\$2.60 (as of 7/5/2013)
Conservative 18-Month Projection:	\$33.20
Very Conservative 12-Month Projection:	\$16.60
Immediate STRONG BUY Target Price:	\$8.30

Note: As with any investment there is always a particle of risk, but also a potential to reap rich returns. To minimize risk, I recommend limiting your investment to 10% of your portfolio.

listing on the NYSE Markets—and yes, that means more Anticipatory Momentum worldwide.

They've secured the services of Akerman Senterfitt, a leading U.S.-based law firm with more than 550 lawyers waist-deep in extensive securities industry experience to get the uplisting to NYSE Markets.

The news is really a mixed bag.

First, it reinforces the credibility of this stock.

Second, it means that the uplisting will put Biologix in the international mainstream spotlight.

And remember...Biologix is OPENING for BUSINESS October 2013 creating a new revenue stream to further support its case for listing on the New York Stock Exchange.

So, if you wait to act after the listing, you'll have missed the great leverage now offered by getting in front of this amazing opportunity.

This factor alone could drive up the price 1,176.92%—which makes it imperative that you get in now for the biggest potential profits. Wait too long and the wave will pass you by.

Reason #5: The Future Potential for Acquisition

Keep in mind that *anticipatory momentum* doesn't just mean individual investors. It also means the deep pocket multinational pharmaceuticals—Big Pharma—are also keeping a close eye on potential acquisition targets.

The big reason? The answer is two-fold.

First, they're looking to grab small companies like Biologix Hair that have already spent time and mountains of money on research and development. That's always the case.

But, the second reason is not as obvious.

Big Pharma is in a race against time to find new revenue-generating patents as their current ones are expiring one after the next.

When one of these pharmaceutical giants decides to pounce, you better be onboard because the payoff would be significant. Just look at these multibillion biotech takeovers over the last few years...

- ◆ Celgene buys out Abraxis BioScience for \$2.9 billion
- ◆ Pfizer buys out King Pharmaceuticals for \$3.6 billion.
- ◆ Merck buys out Millipore for \$5.2 billion
- ◆ **And Novartis buys out Alcon for a whopping \$41 billion**

And even if Big Pharma doesn't bite, there are hundreds of other companies who could potentially want to see Biologix folded into their own existing revenue pipeline.

Aderans—the Japanese hair restoration company—just bought Hair Club from Regis Corporation for \$163.5 million this year. They also own Bosley Hair,

the hair transplant company.

We can assume that Biologix could eventually trade with a market cap substantially higher than \$1 billion as it progresses with the FDA and NYSE listing, this stock could easily see \$33.20 a share.

And in a moment I'll reveal to you exactly how I came to these numbers—a formula based on EXTREMELY CONSERVATIVE ASSUMPTIONS.

Suffice to say that \$33.20 is a static number subject to upward revision whenever any new clinician licensing data is reported that adds to the already impressive 3,284,065 captive patient base controlled by the 276 clinics contracted with Biologix.

Remember, Vertex shot up 55% in just one day on more than 24 million shares of trading volume as they advanced to Phase II clinical trials with a drug estimated to reach only 70,000 people around the world.

Biologix could potentially reach hundreds of millions of people worldwide for both preventative and regenerative treatment.

What's more—as I've said repeatedly—Biologix is OPENING for BUSINESS October 2013. This is a new revenue stream, the first of many, opening up in Colombia as Biologix awaits regulatory approval in major Western markets.

And if (or when) Aderans (or another company) pick up on this news, Biologix could wind up in the buyout crosshairs. And that can only mean good news for investors who act now.

Frankly, I really can't predict how much Biologix's stock might be worth in a buyout. That depends on how much money is changing hands and other factors. But I can say that my 1,176.92% estimate would be on the extremely conservative side. Here's how I came to that figure...

Speedy Retirement Money is in the Math

Here's how I came to some VERY CONSERVATIVE projections.

The current cost of producing a single treatment of Biologix Revive is well less than \$20. Biologix estimates the anticipated wholesale price for a single treatment of Biologix Revive to be \$250 per treatment—a gross sales margin of approximately 1,250% for each and every patient treated.

Now let's make a few ridiculously Conservative Assumptions.



MARIE'S STORY: Take a very personal look into how Biologix is dramatically changing lives for the better.

FREE Profit Alerts!

Sign up now to receive news and timely updates to my ultra-conservative price calculations!

Speed your way to retirement with the latest up-to-the-minute news and information about Biologix (BLGX) and other profitable opportunities—exclusive to members of my Speed Retirement System.

Sign up below for your FREE Profit Alerts.

Conservative Assumption 1: Despite a raging \$3.5 billion hair loss industry in the U.S. alone, let's assume that **not a single person** outside the universe of existing patients from Biologix's contracted clinics is interested in their hair loss breakthrough.

Conservative Assumption 2: The total number of likely candidates according to contracted clinics is 1,315,926 patients. Let's assume ALL of them just want to stop their hair from falling out in the future. In other words... just hair loss PREVENTION clients who come in for **just bi-annual treatments**.

This is in contrast to restoration clients who would require monthly treatments for the first several months, followed by bi-monthly, then quarterly treatments before eventually ending up on the same bi-annual maintenance program as prevention clients.

So based on that assumption, the number of actual treatments would be 1,315,926 patients x 2 treatments.

Now we must account for a 24-month 10% pricing discount clinics receive as part of their pre-FDA contracting agreement with Biologix.

At a sales price of \$250 per treatment, this 10% represents a \$25 discount per treatment. So we are now looking at \$225 per treatment.

Multiply 2,631,852 treatments by \$225 and you come up with \$592,166,700 in gross revenue. **But there's one last thing to make this estimate legit.**

We need to subtract a royalty of \$20 per treatment Biologix pays to their inventor group. So we take the 2,631,852 treatments and multiply by \$20. That gives us \$52,637,040 which we subtract from \$592,166,700.

That gives a grand total of \$539,529,660 in gross revenue!

That's more than a half BILLION dollars in first year gross revenue!

Now, since the cost of goods sold is reportedly "well less than \$20," we can accurately forecast cost of goods sold in the first year to be at the most **\$52,637,040. (Yes, the same amount as the royalty.)**

So here's what the first year net sales revenue looks like:

• Gross Revenue	\$539,529,660
• Cost of Goods Sold	\$52,637,040
• Net Revenue	\$486,892,620

By applying my ridiculously conservative risk assessment of 90% against this revenue calculation, we find a risk-adjusted revenue projection of **\$48,689,262**.

Now, with only 58,926,750 shares outstanding at the time of writing this report, that represents about 83 cents per share in net revenue.

First Name*:

Last Name:

Email*:

Confirm Email*:

Alert Me!

*Required

Now biotechs tend to command high price-to-earnings ratios well in excess of 20 times. But I'm sticking with an ultra-conservative multiple of only 10X, which I will apply to my net revenue projection.

So the value I see on the extreme low side for the shares of this company at this time is approximately \$8.30 per share (83 cents x 10).

My ridiculously conservative 90% assessment drops to 80% with the completion of BIT's series of tests prior to commencing formal FDA clinical trials.

The impact would be seen by an automatic doubling of the stock price valuation. So \$8.30 per share turns into \$16.60 per share.

Okay, I have one more major impact occurrence that could significantly reduce the FDA risk assessment, this time from 80% to 60%.

If and when Biologix submits its final formula for worldwide patent protection, and its Biologix Revive hair formula, then I'll immediately drop my risk assessment in half in recognition of both the time and money savings to be realized by Biologix AND...

The higher probability that this drug is an immediate takeover target... and I do mean immediate!

There is no way Big Pharma will wait past that point. Their calculators can crunch the same numbers as mine. And I am quite certain that management and shareholders will not be silly enough to vote in favor of anything other than a reasonable bid—**which would NOT be based on my ridiculously conservative assumptions.**

If and when Biologix submit its final formula for worldwide patent protection, I would see a current risk adjusted stock price of \$33.20 per share as representing a very conservatively calculated value.

I expect that Biologix will see the completion of BIT's tests, the filing of its final PCT patent in Geneva, and receive FDA approval that Biologix can start at Phase III clinical trials because of all of the work they have already done over the past 20+ years – including pre-clinical trials on more than 5,000 patients!

Therefore, I am comfortable making the following price forecasts, which include risk assessments that coincide with realistic R&D timelines:

- ◆ **Immediate target price: \$8.30 per share**
- ◆ **12-month target price: \$16.60 per share**
- ◆ **18-month target price: \$33.20 per share**



JULIANA'S STORY: Take a very personal look into how Biologix is dramatically changing lives for the better.

Please note that all of the above forecasts will be adjusted upwards for any additional clinician licensing data reported by Biologix that is not currently part of the value matrix calculations.

Biologix Hair (BLGX) is still flying under the radar of most analysts and investors. If you wait too long, YOU WILL MISS OUT on a big opportunity.

If you have \$5,000 to \$10,000 in capital you'd like to invest for potentially strong returns over the next 12 to 18 months, then I highly recommend you get a piece of BLGX now while it's still hovering in the \$2.60 range.

Call your discount broker or go online and buy shares of Biologix Hair now.

Important: For more specific stock recommendations—like Biologix—to help you speed your way to an earlier retirement using my exclusive hyper-compounding strategies, I urge you to become a member of my ***Speed Retirement System***.

It's vital you don't miss my up to the minute buy-sell-and hold alerts that have helped investors just like you start seeing their retirement dreams realized in as little as 5 short years. Here's how.

Speed your way to retirement in as little as 5 years?

I've been helping investors make money for nearly 15 years—when the economy was booming...crashing...or dead flat.

Since 2007, the year I first started documenting my trades, I've averaged 76.2% profits. My average net gain is 32%, and that includes all the losers.

In fact, if you'd had access to my trades since 2007, you could have turned \$10,000 into \$2.2 million, just by putting 10% of your portfolio into every one of my trades.

If you just did what I did, you'd be retired by now.

Skeptical? You can download my performance charts [RIGHT HERE](#)

Still, there's a big catch here. Namely, if you look at this chart of my trades, you can see how it would have been theoretically possible to make \$2.2 million. But it's also unrealistic, however, because your positions would have become so large, you'd **literally be affecting the price of the stock.**

So what do you do? The answer is a simple strategy that makes the Speed Retirement System so successful—Hyper-Compounding.

With hyper-compounding you simply take your gains (just your gains!) from one position and reinvest it in the next position. The money you make goes right back to work for you, and you make more and more money each time, reinvesting and compounding your gains. It's simple and dramatically lowers your risk.

My Stock Matrix Pricing Formula:	Now let's plug in the actual numbers as of the end of April 2013:
Total # of existing patients estimated for the Biologix Hair Therapy System™	(1,315,926)
x2 (Represents bi-annual treatment schedule)	(2)
x\$205 (Represents net revenue per treatment to Biologix)	x (\$225)
-\$52,637,040 (Represents Royalty payment to Inventor group @ \$20 per treatment)	-\$52,637,040
-\$52,637,040 (The cost of goods sold @ \$20 a treatment)	-\$52,637,040
= Net First Year Revenue	\$486,892,620
x .10 (Represents 90% risk adjustment)	x (.10)
= Risk Adjusted Net Revenue	= \$48,689,262
+ # of Biologix shares outstanding	+ 58,926,750
= Net revenue Per Share	= \$.83 net revenue per share
x10 (Conservative growth multiple)	x (10)
= My Current Fair Value Price Est. Per Share	= \$8.30/share - My Current Fair Value Price Target
x2 (Represents 10% drop in risk adjustment following BIT work completed)	x (2)
= My 12-Month Price Projection	= \$16.60/share - My 12-Month Price Projection
x2 (Represents 20% drop in risk adjustment after submitting its final formula for worldwide patent protection)	x (2)
= My 18-Month Price Projection	= \$33.20/share - My 18-Month Price Projection

Savvy Investor Alert: This formula could change with each new update of clinician licensing data or relevant FDA-approval or new R&D data. Stay on top of these details and my new projections. [ENTER YOUR EMAIL ADDRESS NOW](#) to be alerted of significant new information that could drive Biologix's stock price northward.

So let's see how hyper-compounding's less risky approach works in the real world. What happens if you invested **10% of your portfolio per trade each time I made a recommendation?**

- ◆ **In 2008, you would have turned \$10,000 into \$58,935.89—a 589% return while only risking a reasonable portion of your portfolio!**
- ◆ In 2009, my performance dropped and I only earned **280.3% on all my recommendations**. Still, if you followed my trusted 10% rule, along with my hyper-compounding method, you would have still finished the year with **\$165,191.32**.
- ◆ In 2010, I bounced back despite having 24 losers for the year my winners were strong enough to produce a **426.3% gain overall turning your \$10,000 account into \$538,979.90 in pure profit**.
- ◆ **In 2011 I produced a 412.4% return.**

Chances are that's a lot better than what your portfolio has performed over the same time period.

But if you look at my track record, you know that I also have some pretty big losers too. So losses are always possible.

My answer to that is... when you win 76.2% of the time... you follow a **hyper-compounding** strategy... and you **manage your money** properly... so that your winners not only cancel out your losers...

They put you WAY AHEAD!

Just imagine getting monthly income checks from your portfolio by the end of the third year. They're \$10,739... \$25,982...\$57,753... or more.

All from a modest \$10,000 account when you started—without adding any more money to the portfolio outside of the returns you generate!

To learn more about my Speed Retirement System and how you can test-drive it RISK-FREE for 60 days, CLICK the link below



Get started on a system that has proven successful almost 76.2% of the time turning \$10,000 into **\$2.2 million** in just 5 years—whether the market was up, down or sideways. Watch the VIDEO now.

To a prosperous nest egg,

Ian Cooper
Speed Retirement System

What YOU Should Consider Now

- 1 Learn more about Biologix Hair Inc. (BLGX) by visiting their website at www.BiologixHair.com
- 2 Go online now or call your discount broker to invest in Biologix Hair Inc. (BLGX)
- 3 Join the hundreds of investors who are profiting from my **Speed Retirement System** and receive my buy, hold and sell recommendations on BLGX and other stocks. [CLICK HERE](#)

P.S. My Speedier Retirement Super Bonus—And just for trying out the Speed Retirement System, I'll also send you a copy of my new investment report, **My Global Biotech Bonanza Stock for 2013-14** detailing more reasons why you should be taking a closer look at Biologix Hair (BLGX). It's a \$19 value you get FREE when you subscribe.

To learn more about my Speed Retirement System and how you can test-drive it RISK-FREE for 60 days, CLICK the link below



Disclaimer: *Ian Cooper's Speed Retirement System* is an independent circulation newsletter. This online report is a solicitation for subscriptions and a paid promotional advertisement of the featured Company. Market Authority, Inc. received an editorial fee of ten thousand dollars from Gruppen Investments, LTD. This company was chosen to be profiled after *Ian Cooper's Speed Retirement System* completed due diligence on the company. Market Authority and *Ian Cooper's Speed Retirement System* expect to generate subscriber revenue and new online newsletter subscribers, the amount of which is unknown at this time, resulting from the online distribution of this report. Gruppen Investments, LTD paid six thousand three hundred dollars to advertising agencies for the costs of creating this report online, in an effort to build investor awareness. This report does not provide an analysis of a company's financial position. The featured Company's financial position and all other information regarding the featured Company should be verified directly with the Company. Information about many publicly traded companies and other relevant information can be found at the Securities and Exchange Commission's website at www.sec.gov. The information contained herein contains forward-looking information within the meaning of section 27a of the Securities Act of 1933, as amended, and section 21e of the Securities Exchange Act of 1934, as amended, including statements regarding expected growth of the featured Company. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act, statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the Company's actual results of operations. Factors that could cause actual results to differ include the size and growth of the market, ability of the Company to fund its capital requirements in the near term and in the long term, pricing pressures, technology issues, etc. It is recommended that any investment in any security should be made only after consulting with your investment advisor and only after reviewing all publicly available information, including the financial statements of the company. This online report is not intended to be, nor should it be construed as, an offer to buy or sell, or a solicitation of an offer to buy or sell securities, or as a recommendation of the purchase of the featured Company's securities. The information in this online report is believed to be reliable, but its accuracy cannot be guaranteed.

Copyright © 2013 Speed Retirement System. All rights reserved.